Does Inhibiting the Renin-Angiotensin System Help Patients After TAVR?

In an observational study, prescribing RAS inhibitors is associated with lower mortality in patients with heart failure and transcatheter aortic-valve replacement.

Left ventricular (LV) pressure overload from severe aortic stenosis contributes to marked myocardial remodeling, which in turn could contribute to adverse outcomes. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) modulate LV remodeling, which could explain their benefit in treating heart failure with reduced ejection fraction (HFrEF). To assess the relationship between the prescription of renin-angiotensin system (RAS) inhibitors and outcomes after transcatheter aortic-valve replacement (TAVR) for severe aortic stenosis, investigators used the Society of Thoracic Surgeons and American College of Cardiology's Transcatheter Valve Therapy (TVT) Registry to identify 21,312 individuals aged ≥65 who underwe…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Does Inhibiting the Renin-Angiotensin System Help Patients After TAVR?

Topics

Reviewing Author